Evidence map›Paper›PMID 30592740›Full record

ArticlePloS one2018

Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancer.

Helga Hagman, Pär-Ola Bendahl, Jon Lidfeldt, Mattias Belting, Anders Johnsson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Helga HagmanDepartment of Clinical Sciences Lund, Section of Oncology and Pathology, Lund University, Lund, Sweden.ORCID 0000-0002-4427-1123
Pär-Ola BendahlDepartment of Clinical Sciences Lund, Section of Oncology and Pathology, Lund University, Lund, Sweden.
Jon LidfeldtDepartment of Clinical Sciences Lund, Section of Oncology and Pathology, Lund University, Lund, Sweden.
Mattias BeltingDepartment of Clinical Sciences Lund, Section of Oncology and Pathology, Lund University, Lund, Sweden.
Anders JohnssonDepartment of Clinical Sciences Lund, Section of Oncology and Pathology, Lund University, Lund, Sweden.
Lund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProlonged angiogenesis inhibition may improve treatment outcome in metastatic colorectal cancer (mCRC) patients. However, due to the complexity of the angiogenic pathways there is a lack of valid predictive biomarkers for anti-angiogenic agents. Here, we describe and optimize a procedure for simultaneous dynamic profiling of multiple angiogenesis related proteins in patient serum to explore associations with the response and acquired resistance to anti-angiogenic therapy. MATERIALS AND

methodsPatients (n=22) were selected from a clinical trial investigating maintenance treatment with bevacizumab alone after response to induction chemotherapy + bevacizumab in mCRC. Serum samples were analysed for 55 unique angiogenesis related proteins using a commercial proteome profiler array and a publicly available image analysis program for quantification. Samples were collected at baseline before induction treatment start, at start of maintenance treatment, and at end of treatment after tumour progression. MAIN RESULTS AND

conclusionFor eight proteins, the antibody array signals were below detection range in all patient samples. None of the proteins showed levels at baseline or at start of maintenance with strong evidence for correlation to time to progression (lowest nominal p-value 0.03). The dynamic ranges of protein levels measured during the induction treatment period and during the maintenance period were analysed separately for time trends. Evidence for changing trends (up/down) in the levels of MMP-8, TIMP-4 and EGF was observed both during response to induction treatment and at progressive disease, respectively. For three of the proteins (IL-8, Activin A and IGFBP-2), weak evidence for correlation between increasing protein levels during induction with chemotherapy and bevacizumab and time to progression was observed. In conclusion, semi-quantitative profiling of angiogenesis related proteins in patient serum may be a versatile tool to screen for protein patterns aiming at identifying resistance mechanisms of anti-angiogenic treatment in patients with mCRC.

Indexed as

ActivinsAdultAgedAngiogenesis Inducing AgentsAntibodies, Monoclonal, HumanizedBevacizumabBiomarkers, TumorColorectal NeoplasmsEpidermal Growth FactorFemaleHumansInsulin-Like Growth Factor Binding Protein 2MaleMatrix Metalloproteinase 8Middle AgedProtein Array Analysisactivin AActivinsAngiogenesis Inducing AgentsAntibodies, Monoclonal, HumanizedBevacizumabBiomarkers, TumorEpidermal Growth FactorInsulin-Like Growth Factor Binding Protein 2Matrix Metalloproteinase 8Tissue Inhibitor of Metalloproteinase-4Tissue Inhibitor of Metalloproteinases

Identifiers

PMID30592740
PMCPMC6310295
OpenAlexW2907246287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.